Granules India Anakapally facility gets EU GMP certificate
Hyderabad: Granules India Limited has announced that the Company's Unit V facility located at Anakapally, Visakhapatnam, Andhra Pradesh, India received EU GMP certificate for Active Pharmaceutical Ingredients (APIs) and Finished Dosages (FDs).
The EU (National Centre For Public Health And Pharmacy, Hungary) Authority conducted the audit of the facility in the month of November 2024.
This facility manufactures APIs & formulations of oncology and non-oncology products.
Read also: Granules India appoints Dr Rajesh Kapoor as Global Head of Quality
Granules India Limited, incorporated in 1991 is a vertically integrated Indian pharmaceutical company headquartered in Hyderabad. Amongst the few pharmaceutical companies in the world to be present across the manufacturing of the entire pharmaceutical value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs), Granules products are distributed to over 300+ customers in regulated and semiregulated markets with a global presence extending to over 80+ countries with offices across India, US and UK. The Company has 10 manufacturing facilities out of which 8 are located in India and 2 are in the USA and has regulatory approvals from the US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.
Read also: Granules India Unit V facility receives USFDA EIR with 'No Action Indicated' status
